An Update on Botulinum Toxin in Neurology.

Botulinum neurotoxin (BoNT) is an effective treatment for many neurologic disorders. This article gives a comprehensive overview of the clinical applications of BoNT across the field of neurology.

• Publication year

  2021

• Venue

  Neurologic clinics

• Publication date

  2021-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ncl.2020.09.014PMID 33223084
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-dose Botulinum Toxin Therapy: Safety, Benefit, and Endurance of Efficacy

  2020cited by this paper
• Efficacy and Safety of PrabotulinumtoxinA for the Treatment of Glabellar Lines in Adult Subjects: Results From 2 Identical Phase III Studies

  2019cited by this paper
• An update on new and unique uses of botulinum toxin in movement disorders

  2018cited by this paper
• Pilot Single-Blind Trial of AbobotulinumtoxinA in Oromandibular Dystonia

  2018cited by this paper
• The Expanding Therapeutic Utility of Botulinum Neurotoxins

  2018cited by this paper
• Botulinum toxin: A review of the mode of action in migraine

  2018cited by this paper
• Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose‐Escalation Multicenter Study

  2018cited by this paper
• Botulinum Toxin for the Treatment of Hand Tremor

  2018cited by this paper
• Management of cervical dystonia with botulinum neurotoxins and EMG/ultrasound guidance

  2018cited by this paper
• Towards flexible and tailored botulinum neurotoxin dosing regimens for focal dystonia and spasticity - Insights from recent studies.

  2018cited by this paper
• Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine

  2018cited by this paper
• Liquid Formulation of AbobotulinumtoxinA Exhibits a Favorable Efficacy and Safety Profile in Moderate to Severe Glabellar Lines: A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trial

  2018cited by this paper
• OnabotulinumtoxinA for Lower Limb Spasticity: Guidance From a Delphi Panel Approach

  2017cited by this paper
• OnabotulinumtoxinA Injection for Poststroke Upper‐Limb Spasticity: Guidance for Early Injectors From a Delphi Panel Process

  2017cited by this paper
• Muscle Selection for Focal Limb Dystonia

  2017cited by this paper
• Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry.

  2017cited by this paper
• Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity

  2017cited by this paper
• Botulinum toxin: State of the art

  2017cited by this paper
• Botulinum Toxin for the Treatment of Tremor and Tics

  2016cited by this paper
• The phenomenology and treatment of idiopathic adult-onset truncal dystonia: a retrospective review

  2016cited by this paper
• Does the method of botulinum neurotoxin injection for limb spasticity affect outcomes? A systematic review

  2016cited by this paper
• Determinants of disability in cervical dystonia.

  2016cited by this paper
• Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice

  2016cited by this paper
• Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm

  2016cited by this paper
• Systematic review of botulinum toxin treatment for oromandibular dystonia

  2016cited by this paper
• Botulinum Toxin Treatment of Cervical Dystonia

  2016cited by this paper
• Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache

  2016cited by this paper
• Botulinum toxin drugs: brief history and outlook

  2016cited by this paper
• Botulinum Toxin: The Story of Its Development for the Treatment of Human Disease

  2015cited by this paper
• Historical and current perspectives on Clostridium botulinum diversity.

  2015cited by this paper
• OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: A Systematic Literature Review

  2015cited by this paper
• Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE).

  2015cited by this paper
• Botulinum toxins for the prevention of migraine in adults.

  2015cited by this paper
• Clinical differences between botulinum neurotoxin type A and B.

  2015cited by this paper
• Sensory aspects of movement disorders.

  2014cited by this paper
• Drooling in Parkinson's disease: a review.

  2014cited by this paper
• Long-term therapy of benign essential blepharospasm and facial hemispasm with botulinum toxin A: retrospective assessment of the clinical and quality of life impact in patients treated for more than 15 years

  2014cited by this paper
• Botulinum Toxin Therapy for Cervical Dystonia: The Science of Dosing

  2014cited by this paper
• Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A

  2013cited by this paper
• Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.

  2013cited by this paper
• Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders.

  2013cited by this paper
• Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines.

  2012cited by this paper
• Immunogenicity of botulinum toxins

  2012cited by this paper
• Safety and effectiveness of microvascular decompression for treatment of hemifacial spasm: a systematic review

  2012cited by this paper
• Factors associated with quality of life in hemifacial spasm and blepharospasm during long-term treatment with botulinum toxin

  2011cited by this paper
• Clinical features of patients with blepharospasm: a report of 240 patients

  2011cited by this paper
• Treatment of complex cervical dystonia with botulinum toxin: involvement of deep-cervical muscles may contribute to suboptimal responses.

  2011cited by this paper
• Characterization of diffusion and duration of action of a new botulinum toxin type A formulation.

  2011cited by this paper
• Botulinum toxin A versus B in sialorrhea: A prospective, randomized, double‐blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease

  2011cited by this paper
• Global prevalence of chronic migraine: A systematic review

  2010cited by this paper
• OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

  2010cited by this paper
• OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

  2010cited by this paper
• Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well‐Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program

  2010cited by this paper
• Manual of Botulinum Toxin Therapy: Treatment of oromandibular dystonia

  2009cited by this paper
• European consensus table on the use of botulinum toxin type A in adult spasticity.

  2009cited by this paper
• Efficacy of botulinum toxin in severe Tourette syndrome with dystonic tics involving the neck.

  2008cited by this paper
• Botulinum toxin type A in the treatment of patients with cervical dystonia

  2008cited by this paper
• Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review) Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

  2008cited by this paper
• Botulinum toxin treatment of axial and cervical dystonia

  2007cited by this paper
• The treatment of cervical dystonia with botulinum toxins

  2007cited by this paper
• Pallidal deep brain stimulation in patients with cranial–cervical dystonia (Meige syndrome)

  2007cited by this paper
• Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study.

  2007cited by this paper
• Botulinum toxin type B (Myobloc®) in subjects with hemifacial spasm: Results from an open‐label, dose‐escalation safety study

  2007cited by this paper
• Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations

  2006cited by this paper
• Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study

  2006cited by this paper
• Botulinum toxin changes intrafusal feedback in dystonia: A study with the tonic vibration reflex

  2006cited by this paper
• Treatment of cervical dystonia with botulinum toxins

  2006cited by this paper
• Beyond BOTOX: advantages and limitations of individual botulinum neurotoxins.

  2005cited by this paper
• Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.

  2005cited by this paper
• Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease.

  2004cited by this paper
• Treatment of phonic tics in patients with Tourette’s syndrome using botulinum toxin type A

  2004cited by this paper
• A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease

  2004cited by this paper
• Botulinum toxin therapy for cervical dystonia.

  2003cited by this paper
• Muscle overactivity and movement dysfunction in the upper motoneuron syndrome.

  2003cited by this paper
• Blepharospasm

  2002cited by this paper
• Botulinum toxin for simple motor tics

  2001cited by this paper
• Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial

  2000cited by this paper
• Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia

  2000cited by this paper
• Effect of muscle activity immediately after botulinum toxin injection for writer's cramp

  1999cited by this paper
• Historical aspects of botulinum toxin

  1999cited by this paper
• Extensor truncal dystonia: Successful treatment with botulinum toxin injections

  1998cited by this paper
• Clostridium botulinum was named because of association with “sausage poisoning”

  1998cited by this paper
• The variability in the clinical effect induced by botulinum toxin type A: The role of muscle activity in humans

  1997cited by this paper
• Clinical features and natural history of axial predominant adult onset primary dystonia

  1997cited by this paper
• Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm

  1997cited by this paper
• DYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1

  1997cited by this paper
• Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening.

  1996cited by this paper
• A randomized, double‐blind, placebo‐controlled study to evaluate botulinum toxin type A in essential hand tremor

  1996cited by this paper
• Historical note on the therapeutic use of botulinum toxin in neurological disorders.

  1996cited by this paper
• “Apraxia of lid opening,” a focal eyelid dystonia: Clinical study of 32 patients

  1994cited by this paper
• Botulinum a toxin treatment of hemifacial spasm and blepharospasm.

  1993cited by this paper
• Treatment of hemifacial spasm with botulinum toxin

  1992cited by this paper
• Botulinum toxin injection for spasmodic torticollis

  1992cited by this paper
• Botulinum toxin treatment of tremors

  1991cited by this paper
• Botulinum A toxin for cranial‐cervical dystonia

  1987cited by this paper
• Double-blind study of botulinum toxin in spasmodic torticollis.

  1986cited by this paper
• A Pilot Study on the Use of Botulinum Toxin in Spasmodic Torticollis

  1985cited by this paper
• A New Anaerobic Bacillus and Its Relation to Botulism

  1979cited by this paper

• INTERCORRÊNCIAS EM PROCEDIMENTOS ESTÉTICOS INJETAVEIS E IMPACTOS NA VIDA DO PACIENTE

  2025cites this paper
• Orthodontic considerations for managing patients with functional movement disorders: a narrative review and clinical guide

  2025cites this paper
• Severe Botulism after Intragastric Botulinum Toxin-A Injection: A Case Series

  2024cites this paper
• Exploring New and Potential Indications for Botulinum Toxin Treatment: An Updated Literature Review

  2024cites this paper
• Analysis of a Collaborative Research Network of Botulinum Toxin Clinical Trials

  2024influential citation
• Botulinum Toxin for the Management of Pelvic Floor Tension Myalgia and Persistent Pelvic Pain

  2023cites this paper
• Endoscopic botulinum toxin injection combined with balloon dilatation for treatment of cricopharyngeal achalasia in patient with brainstem stroke.

  2023cites this paper
• Guidelines for the Use of Botulinum Toxin in Otolaryngology From the Korean Society of Laryngology, Phoniatrics and Logopedics Guideline Task Force

  2023cites this paper
• Exploring the Central Mechanisms of Botulinum Toxin in Parkinson’s Disease: A Systematic Review from Animal Models to Human Evidence

  2023cites this paper
• Clinical Application of Botulinum Toxin for Hemifacial Spasm

  2023cites this paper
• Botulinum Neurotoxin A4 Has a 1000-Fold Reduced Potency Due to Three Single Amino Acid Alterations in the Protein Receptor Binding Domain

  2023cites this paper
• A large travel-associated outbreak of iatrogenic botulism in four European countries following intragastric botulinum neurotoxin injections for weight reduction, Türkiye, February to March 2023

  2023cites this paper
• Medicamentos bioterapéuticos: uso de toxinas botulínicas en la era de biosimilares

  2023cites this paper
• Clinical efficacy of escitalopram combined with botulinum toxin A in patients with generalized anxiety disorder and comorbid headache

  2023cites this paper
• Sensory Symptoms Associated with Aesthetic Botulinum Toxin A Treatments

  2022cites this paper
• Advances in Clostridial and Related Neurotoxins

  2022cites this paper
• The Multispecialty Toxin: A Literature Review of Botulinum Toxin

  2022cites this paper
• Botulinum Neurotoxins in Central Nervous System: An Overview from Animal Models to Human Therapy

  2021cites this paper
• Botulinum Neurotoxins (BoNTs) and Their Biological, Pharmacological, and Toxicological Issues: A Scoping Review

  2021cites this paper